Evaluation of serum alpha fetoprotein-L3 as an accuracy novel biomarker for the early diagnosis of hepatocellular carcinoma in Egyptian Patients

Aims Hepatocellular carcinoma is one of the most aggressive malignant tumors and has limited treatment options. Needle-guided biopsies have been utilized as a tool to diagnose malignant focal hepatic lesions. These techniques are discouraged because of their complications. Nowadays, alpha fetoprotein is the most widely used tumor marker for screening and diagnosis of hepatocellular carcinoma. Nevertheless, this marker has limitations. The diagnostic role of plasma osteopontin as an adjuvant or alternative marker to alpha fetoprotein to detect hepatocellular carcinoma in Egyptian patients with focal hepatic lesions was evaluated in this study. Subject and methods Eighty participants were recruited from the Egyptian National Liver Institute and were self-assigned to three groups, namely, focal hepatic lesions (n = 40), liver cirrhosis (n = 20), and controls (n = 20). Participants' plasma osteopontin and serum alpha fetoprotein levels were determined and were compared across the three groups. Results The discriminatory ability of plasma osteopontin for hepatocellular carcinoma was lower than that of alpha fetoprotein. Osteopontin and alpha fetoprotein were not correlated with each other. Neither the gender nor the age of the patients showed a significant association with plasma osteopontin level. Conclusion Measuring plasma osteopontin level alone has no advantage over serum alpha fetoprotein in patients with focal hepatic lesions due to chronic liver disease.

Download Full-text

Is serum alpha-fetoprotein (AFP) useful in early diagnosis of hepatocellular carcinoma (HCC)? A prospective study

Journal of Hepatology ◽

10.1016/0168-8278(91)91383-r ◽

1991 ◽

Vol 13 ◽

pp. S102

Author(s):

S. Bruno ◽

S. Rossi ◽

F. Borzio ◽

M. Borzio ◽

R. Santambrogio ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

Early Diagnosis ◽

Prospective Study ◽

Alpha Fetoprotein ◽

Serum Alpha Fetoprotein ◽

A Prospective Study

Download Full-text

Early Diagnosis of Hepatocellular Carcinoma with Lectin Electrophoresis of Serum Alpha-Fetoprotein

Tumor Biology ◽

10.1159/000217551 ◽

1988 ◽

Vol 9 (2-3) ◽

pp. 110-115 ◽

Cited By ~ 11

Author(s):

H. Taga ◽

H. Hirai ◽

H. Ishizuka ◽

H. Kaneda

Keyword(s):

Hepatocellular Carcinoma ◽

Early Diagnosis ◽

Alpha Fetoprotein ◽

Serum Alpha Fetoprotein

Download Full-text

MicroRNAs as Potential Diagnostic and Prognostic Biomarkers in Hepatocellular Carcinoma

Current Drug Targets ◽

10.2174/1389450120666190307095720 ◽

2019 ◽

Vol 20 (11) ◽

pp. 1129-1140 ◽

Cited By ~ 8

Author(s):

Seyed Mostafa Parizadeh ◽

Reza Jafarzadeh-Esfehani ◽

Maryam Ghandehari ◽

Fatemeh Goldani ◽

Seyed Mohammad Reza Parizadeh ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

Early Diagnosis ◽

Biological Activities ◽

Radical Resection ◽

High Rate ◽

Average Survival ◽

Specific Tumor ◽

Serum Alpha Fetoprotein ◽

Novel Biomarkers ◽

Patients Experience

Hepatocellular carcinoma (HCC) is a common cancer, and the second most common cause of cancer-associated death globally. One of the major reasons for this high rate of mortality is a failure to make an early diagnosis. The average survival in untreated HCC patients is estimated to be approximately three months. The 5-year overall survival rate after radical resection is about 15-40% and within two years, more than two third of patients experience a relapse. To date, the most common biomarker which has been used for the diagnosis of HCC is serum alpha-fetoprotein (AFP). However, there is a lack of sensitive and specific tumor biomarkers for the early diagnosis of HCC. MicroRNAs are a class of short endogenous RNA with crucial role in many biological activities and cellular pathways and can be found in various tissues and body fluids. The aim of this review was to summarize the results of recent studies investigating miRNAs as novel biomarkers for the early diagnosis and prognostic risk stratification of patients with this type of liver cancer.

Download Full-text

Role of annexin A2 and osteopontin for early diagnosis of hepatocellular carcinoma in hepatitis C virus patients

Egyptian Liver Journal ◽

10.1186/s43066-019-0004-9 ◽

2019 ◽

Vol 9 (1) ◽

Author(s):

Abd El-Fattah F. Hanno ◽

Fatma M. Abd El-Aziz ◽

Akram A. Deghady ◽

Ehab H. El-Kholy ◽

Aborawy I. Aborawy

Keyword(s):

Hepatocellular Carcinoma ◽

Chronic Hepatitis ◽

Hepatitis C ◽

Early Diagnosis ◽

Positive Predictive Value ◽

Negative Predictive Value ◽

Chronic Hepatitis C ◽

Predictive Value ◽

Annexin A2 ◽

Alpha Fetoprotein

Abstract Background Liver cancer is the fifth most common cancer and the second most frequent cause of cancer-related death globally. Early stages of hepatocellular carcinoma (0&A) can be treated with curative procedures. The aim of this work was to evaluate the role of annexin A2 and osteopontin for early diagnosis of hepatocellular carcinoma in hepatitis C virus patients. Methods The study was carried out on 80 patients classified into two groups. Group A had 40 chronic hepatitis C patients without hepatocellular carcinoma, while group B had 40 chronic hepatitis C patients with early hepatocellular carcinoma (stages; 0&A). All patients were subjected to thorough history taking, clinical examination, liver function tests, renal function tests, serum alpha-fetoprotein, serum osteopontin, and serum annexin A2. Results Serum alpha-fetoprotein was found to be statistically significantly higher in patients with the hepatocellular carcinoma group than the chronic hepatitis C group. The ROC curve for alpha-fetoprotein for detection of HCC was significant, its diagnostic performance was 0.818* (p < 0.001*), and the cutoff point for predicting the probability for HCC was 6.0 (ng/ml) with sensitivity of 77.50%, specificity of 82.50%, positive predictive value of 81.60%, negative predictive value of 78.6%, and accuracy of 80%. Serum osteopontin was found to be statistically significantly higher in patients from the hepatocellular carcinoma group than the chronic hepatitis C group. The ROC curve for osteopontin was significant, its diagnostic performance was 0.739* (p < 0.001*), the cutoff point was 13.2 (ng/ml) with sensitivity of 65.0%, specificity of 90.0%, positive predictive value of 86.70%, negative predictive value of 72.0%, and accuracy of 77.0%. Serum annexin A2 was found to be statistically significantly higher in patients from the hepatocellular carcinoma group than the chronic hepatitis C group. The ROC curve for annexin A2 was significant, its diagnostic performance was 0.927* (p < 0.001*), the cutoff point was 10.1(ng/ml) with sensitivity of 85.0%, specificity of 85.0%, positive predictive value of 85.0%, negative predictive value of 85.0%, and accuracy of 85.0%. Conclusions Osteopontin had better specificity but lower sensitivity than serum alpha-fetoprotein for early diagnosis of hepatocellular carcinoma. Annexin A2 had better diagnostic sensitivity and specificity than alpha-fetoprotein for early diagnosis of hepatocellular carcinoma.

Download Full-text